HWG Holdings LP Has $7.14 Million Stock Position in Natera, Inc. $NTRA

by · The Markets Daily

HWG Holdings LP grew its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 3.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 42,286 shares of the medical research company’s stock after buying an additional 1,379 shares during the period. Natera accounts for approximately 2.1% of HWG Holdings LP’s investment portfolio, making the stock its 14th largest holding. HWG Holdings LP’s holdings in Natera were worth $7,144,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wedmont Private Capital increased its stake in shares of Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after buying an additional 74 shares during the period. Lake Hills Wealth Management LLC increased its stake in shares of Natera by 6.7% in the 2nd quarter. Lake Hills Wealth Management LLC now owns 3,322 shares of the medical research company’s stock valued at $561,000 after buying an additional 210 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Natera in the 2nd quarter valued at $298,000. Pallas Capital Advisors LLC increased its stake in shares of Natera by 28.6% in the 2nd quarter. Pallas Capital Advisors LLC now owns 12,320 shares of the medical research company’s stock valued at $2,081,000 after buying an additional 2,742 shares during the period. Finally, New England Research & Management Inc. acquired a new stake in shares of Natera in the 2nd quarter valued at $262,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

NTRA opened at $175.43 on Thursday. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00. The firm has a market capitalization of $24.08 billion, a PE ratio of -91.85 and a beta of 1.68. The business’s 50-day simple moving average is $156.05 and its 200 day simple moving average is $154.52.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the previous year, the company posted ($0.30) EPS. The business’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NTRA shares. Morgan Stanley reissued an “overweight” rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Barclays reaffirmed an “overweight” rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Cowen reaffirmed a “buy” rating on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Stephens reaffirmed an “overweight” rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $194.00.

Read Our Latest Report on Natera

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00. Following the sale, the insider owned 120,859 shares in the company, valued at approximately $20,137,526.58. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John Fesko sold 678 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $155.46, for a total value of $105,401.88. Following the sale, the insider owned 152,747 shares in the company, valued at $23,746,048.62. The trade was a 0.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 in the last ninety days. Insiders own 5.63% of the company’s stock.

Natera Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).